Search

Author/Creator Dummer, R

1. 1250PEstimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. (23rd October 2018)

Authors:
Dummer, R; Schadendorf, D; Hauschild, A; Santinami, M; Atkinson, V G; Mandala, M; Chiarion Sileni, V; Larkin, J; Nyakas, M S; Dutriaux, C; Haydon, A; Mortier, L; Robert, C; Schachter, J; Feng, X; de Jong, E; Mookerjee, B; Kefford, R; Kirkwood, J M; Long, G V
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1251PAdverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. (23rd October 2018)

Authors:
Atkinson, V G; Hauschild, A; Santinami, M; Mandala, M; Chiarion Sileni, V; Larkin, J; Nyakas, M S; Dutriaux, C; Haydon, A; Mortier, L; Robert, C; Schachter, J; Schadendorf, D; Feng, X; de Jong, E; Mookerjee, B; Kefford, R; Dummer, R; Kirkwood, J M; Long, G V
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 1560PDMajor determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey. (23rd October 2018)

Authors:
Kandolf Sekulovic, L O; Agarwala, S S; Hauschild, A; Guo, J; McArthur, G A; Lorigan, P; Cinat, G; Caglevich, C; Lebbe, C; Rutkowski, P L; Gogas, H; Dummer, R; Neyns, B; Bastholt, L; Wainstein, A; Herceg, D; Banjin, M; Zhukavets, A; Ocvirk, J; Garbe, C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. (28th March 2019)

Authors:
Jansen, Y J L; Rozeman, E A; Mason, R; Goldinger, S M; Geukes Foppen, M H; Hoejberg, L; Schmidt, H; van Thienen, J V; Haanen, J B A G; Tiainen, L; Svane, I M; Mäkelä, S; Seremet, T; Arance, A; Dummer, R; Bastholt, L; Nyakas, M; Straume, O; Menzies, A M; Long, G V
Journal:
Annals of oncology
Issue:
Volume 30:Number 7(2019)
Page Start:
1154
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. LBA44Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). (23rd October 2018)

Authors:
Hodi, F S; Chiarion-Sileni, V; Gonzalez, R; Grob, J J; Rutkowski, P; Cowey, C L; Lao, C; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, P F; Smylie, M; Hill, A G; Hogg, D; Marquez-Rodas, I; Jiang, J; Rizzo, J; Larkin, J; Wolchok, J
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search